Literature DB >> 12518122

Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.

Manuel Moretó1, Manuel Zaballa, Ignacio Casado, Olga Merino, Miguel Rueda, Kléber Ramírez, Raquel Urcelay, Amaia Baranda.   

Abstract

BACKGROUND: Pancreatic sphincter hypertension increases the risk of pancreatitis in patients undergoing ERCP. Glyceryl trinitrate reduces sphincter of Oddi pressure. This study tested the hypothesis that transdermal glyceryl trinitrate could be effective in the prevention of post-ERCP pancreatitis.
METHODS: One hundred forty-four patients undergoing ERCP were randomized: 71 received a 15-mg glyceryl trinitrate patch (glyceryl trinitrate group) and 73 a placebo patch (control group).
RESULTS: In the control group, post-ERCP pancreatitis developed in 11 patients versus 3 in the glyceryl trinitrate group (p < 0.05). Twenty-four hour to baseline serum amylase and lipase ratios were lower in the glyceryl trinitrate group (respectively, 3.6 vs. 7.5, p < 0.05; and 5.3 vs. 27.7, p < 0.05). In a multivariate analysis, glyceryl trinitrate patch and the number of pancreatic injections, but not endoscopic sphincterotomy, were independent risk factors for post-ERCP pancreatitis.
CONCLUSIONS: The results of this study suggest that use of a transdermal glyceryl trinitrate patch protects against post-ERCP pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12518122     DOI: 10.1067/mge.2003.29

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  23 in total

Review 1.  Endoscopic papillotomy, syn. sphincterotomy: results from the past two years.

Authors:  Meinhard Classen; Peter Born
Journal:  Curr Gastroenterol Rep       Date:  2004-04

2.  The effects of contrast agent and intraductal pressure changes on the development of pancreatitis in an ERCP model in rats.

Authors:  Tufan Haciahmetoglu; Cemalettin Ertekin; Kemal Dolay; Fatih Yanar; Hakan Yanar; Yersu Kapran
Journal:  Langenbecks Arch Surg       Date:  2007-08-03       Impact factor: 3.445

3.  Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.

Authors:  Ryan D Madanick; Colm J O'Loughlin; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

Review 4.  New advances in acute pancreatitis.

Authors:  Matthew J DiMagno; Eugene P DiMagno
Journal:  Curr Opin Gastroenterol       Date:  2007-09       Impact factor: 3.287

5.  Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats.

Authors:  Emma Folch-Puy; Susana Granell; Juan L Iovanna; Marc Barthet; Daniel Closa
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

6.  Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo-controlled trial.

Authors:  Jian Yu Hao; Dong Fang Wu; Yue Zeng Wang; Ying Xin Gao; Hai Po Lang; Wei Zhen Zhou
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 7.  Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review.

Authors:  Seyed Sajad Mohseni Salehi Monfared; Hamed Vahidi; Amir Hossein Abdolghaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

8.  Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis.

Authors:  Altug Senol; Ulku Saritas; Halil Demirkan
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

9.  Nitric oxide pathways and evidence-based perturbations in acute pancreatitis.

Authors:  Matthew J DiMagno
Journal:  Pancreatology       Date:  2007-09-25       Impact factor: 3.996

10.  Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial.

Authors:  O Barkay; E Niv; E Santo; R Bruck; A Hallak; F M Konikoff
Journal:  Surg Endosc       Date:  2008-01-24       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.